Precision BioSciences (DTIL) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Voyager Therapeutics (VYGR) over the past year, gaining 12.8% versus a loss of 55.1%. Over five years, VYGR leads with a -42.2% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($185.5 million vs $151.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | VYGR |
|---|---|---|
| Share price | $6.72 | $2.45 |
| Market cap | $185.48M | $150.96M |
| 1-day change | +4.51% | +3.38% |
| YTD return | +54.57% | -39.69% |
| 1-year return | +12.81% | -55.11% |
| 5-year return | -97.81% | -42.20% |
| EPS (TTM) | $-1.35 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $5.55 |
| 52-week low | $3.53 | $2.33 |
| Distance from 52-week high | -30.15% | -55.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +337.50% | +507.76% |
| Average volume | 287.13K | 573.14K |
| Shares outstanding | 27.60M | 61.62M |
| Employees | 67 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed VYGR by 67.9 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
DTIL vs VYGR FAQ
Which is bigger, Precision BioSciences or Voyager Therapeutics?
Precision BioSciences (DTIL) is larger, with a market capitalization of $185.48M compared with $150.96M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, DTIL or VYGR?
DTIL returned +12.81% over the past 12 months, compared with -55.11% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.